Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12677919 | 0.79 | HPGD (0.47) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL4659776 | 0.79 | KMT2A (0.54) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL12601746 | 0.79 | ALDH1A1 (0.54) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL13181083 | 0.76 | ALDH1A1 (0.55) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL10266908 | 0.74 | ALDH1A1 (0.50) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL8061325 | 0.74 | ALDH1A1 (0.48) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL1448063 | 0.73 | KMT2A (0.49) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL11836411 | 0.73 | ALDH1A1 (0.49) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL12601867 | 0.71 | LMNA (0.52) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL8061300 | 0.71 | ALDH1A1 (0.46) | KMT2AALDH1A1MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2399577-A1 | Use of N-containing spirocompounds for the enhancement of cognitive function | Adolor Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071611-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8022060-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | ADOLOR CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-0322164-B1 | ETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1993-09-22 | — | — | EP | disclosed |
| US-5039697-A | Adrenergic stimulants, bronchodilators | GLAXO GROUP LIMITED (GB) | 1991-08-13 | — | — | US | disclosed |
| US-5032609-A | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1991-07-16 | — | — | US | disclosed |
| US-5002966-A | Adrenergic Stimulants | GLAXO GROUP LIMITED (GB) | 1991-03-26 | — | — | US | disclosed |
| EP-0322164-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218186-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | KMT2A 2918/4885ALDH1A1 259/4885MEN1 4606/4885 |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | KMT2A 1540/4885ALDH1A1 2997/4885MEN1 3667/4885 |
| US-20080102031-A1 | Spirocyclic Heterocyclic Derivatives And Methods Of Their Use | OPRK1, OPRD1, OPRL1 | KMT2A 2918/4885ALDH1A1 259/4885MEN1 4606/4885 |
| US-20120165356-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | KMT2A 2918/4885ALDH1A1 259/4885MEN1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.